Wolfgang Glaesner

Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein

Wolfgang Glaesner, Andrew Vick, Rohn Millican et al. · Diabetes/Metabolism Research and Reviews · 2010 · 290 citations

Glycosylation of Erythropoietin Affects Receptor Binding Kinetics:  Role of Electrostatic Interactions

Ryan J. Darling, Uma Kuchibhotla, Wolfgang Glaesner et al. · Biochemistry · 2002 · 116 citations

Glycobiology, Chemical Biology, Electrostatic Interactions +17

An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif

Deepa Balasubramaniam, Oliver C. Schroeder, Anna M. Russell et al. · Journal of Lipid Research · 2022 · 46 citations · Full text

Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide

Zvonko Miličević, Greg Anglin, Kristine D. Harper et al. · Diabetes Obesity and Metabolism · 2016 · 27 citations

A New Approach to Drug Therapy: Fc-Fusion Technology

V. Pechtner, Karanikas CA, Garcia Perez LE et al. · Primary Health Care Open Access · 2017 · 18 citations · Full text

Engineering, Immunology, Immune Regulation +20